Thyrocare Technologies Limited has submitted to the Exchange, Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter.
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.8 pts less than Nifty Microcap 250 and 7.3 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Thyrocare Technologies' Board of Directors met on January 28, 2026, and approved the financial results for the quarter and nine months ended December 31, 2025. The announcement is procedural in nature, confirming the outcome of the board meeting and referencing other matters detailed in an enclosed letter. No specific financial figures, segment performance, or detailed business commentary are disclosed in this headline filing.
This is a routine regulatory filing confirming board approval of quarterly results. Shareholders should look to the actual financial results document for revenue, profit, and margin details to gauge any meaningful impact on the stock.